Tonix Pharmaceuticals to Present at the virtual Fall Investor Summit on November 16th-18th

Rhea-AI Summary

Tonix Pharmaceuticals (NASDAQ:TNXP) will participate in the 2020 Fall Investor Summit from November 16-18. This virtual event will feature 75 companies and over 300 investors, creating a platform for networking and investment opportunities.

Tonix is focused on developing treatments for human diseases, particularly in the central nervous system and immunology fields. Their lead vaccine candidate, TNX-1800, aims to protect against COVID-19, with data expected in 4Q'20. Additionally, their CNS candidate, TNX-102 SL, is in Phase 3 trials for fibromyalgia, with results anticipated later this year.

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Tonix Pharmaceuticals (NASDAQ:TNXP), a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering, will be presenting at this year's virtual Fall Investor Summit on November 16^th-18^th.

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

About Tonix Pharmaceuticals

Tonix is a clinical-stage biopharmaceutical company focused on small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates.

Tonix's lead vaccine candidate, TNX-1800*, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response, with data expected from preclinical studies of TNX-1800 in 4Q'20.

Tonix's lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia with expected results from an interim analysis in September 2020 and topline data in the fourth quarter of 2020.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker (brittney@investorsummitgroup.com)

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at brittney@investorsummitgroup.com

SOURCE: Tonix Pharmaceuticals

View source version on accesswire.com:
https://www.accesswire.com/615988/Tonix-Pharmaceuticals-to-Present-at-the-virtual-Fall-Investor-Summit-on-November-16th-18th

FAQ

When is Tonix Pharmaceuticals presenting at the Fall Investor Summit?

Tonix Pharmaceuticals will present at the Fall Investor Summit from November 16-18, 2020.

What is the focus of Tonix Pharmaceuticals' research?

Tonix Pharmaceuticals focuses on developing small molecules and biologics for treating and preventing human diseases, particularly in the CNS and immunology sectors.

What are the main products in Tonix Pharmaceuticals' pipeline?

Tonix's main products include the vaccine candidate TNX-1800 for COVID-19 and TNX-102 SL, which is in Phase 3 development for fibromyalgia.

What data is expected from Tonix Pharmaceuticals in 4Q'20?

Data from the preclinical studies of TNX-1800 is expected in the fourth quarter of 2020.

What stage is TNX-102 SL in currently?

TNX-102 SL is in Phase 3 development for the management of fibromyalgia.